Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

Michio Kawano(Hiroshima University), Toshio Hirano(Hiroshima University), Tadashi Matsuda(Hiroshima University), Tetsuya Taga(Hiroshima University), Yasuhiro Horii(Hiroshima University), Koji Iwato(Hiroshima University), Hideki Asaoku(Hiroshima University), Bo Tang(Hiroshima University), Osamu Tanabe(Hiroshima University), Hideo Tanaka(Hiroshima University), Atsushi Kuramoto(Hiroshima University), Tadamitsu Kishimoto(Hiroshima University)

Nature

March 1, 1988

10.1038/332083a0

Cited by 1,661

Abstract

Related Papers

Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease

John M. Chirgwin, Alan Przybyla, Raymond J. MacDonald et al.|Biochemistry|1979|22.2k

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

Brian G.M. Durie, Sydney E. Salmon|Cancer|1975|3k

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Toshio Hirano, Kiyoshi Yasukawa, Hisashi Harada et al.|Nature|1986|2.2k

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Jack Gauldie, Carl D. Richards, D.C. Harnish et al.|Proceedings of the National Academy of Sciences|1987|1.7k

Autocrine growth factors and cancer

Michael B. Sporn, Anita B. Roberts|Nature|1985|1.5k